Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 2
2019 4
2020 1
2021 1
2022 3
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR.
Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG, Lee JY, Lee JC, Choi CM, Ji W, Song SY, Choi J, Lee SY, Kim H, Lee SY, Park J, Yoon SH, Joo JH, Oh IJ. Park CK, et al. Among authors: kim yh. J Thorac Oncol. 2023 Aug;18(8):1042-1054. doi: 10.1016/j.jtho.2023.04.008. Epub 2023 Apr 20. J Thorac Oncol. 2023. PMID: 37085032 Free article.
Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial.
Kim YH, Ahn SJ, Moon SH, Kim JH, Kim YC, Oh IJ, Park CK, Jeong JU, Yoon MS, Song JY, Suh CO, Cho KH, Park SH. Kim YH, et al. Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):873-885. doi: 10.1016/j.ijrobp.2022.10.014. Epub 2022 Oct 21. Int J Radiat Oncol Biol Phys. 2023. PMID: 36280151 Clinical Trial.
A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
Park CK, Jeon N, Park HK, Oh HJ, Kim YC, Jeon HL, Kim YH, Ahn SJ, Oh IJ. Park CK, et al. Among authors: kim yh. Cancers (Basel). 2023 Mar 5;15(5):1606. doi: 10.3390/cancers15051606. Cancers (Basel). 2023. PMID: 36900397 Free PMC article.
Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
Jeong JU, Nam TK, Song JY, Yoon MS, Ahn SJ, Chung WK, Cho IJ, Kim YH, Cho SH, Jung SI, Kang TW, Kwon DD. Jeong JU, et al. Among authors: kim yh. PLoS One. 2021 Mar 12;16(3):e0248461. doi: 10.1371/journal.pone.0248461. eCollection 2021. PLoS One. 2021. PMID: 33711055 Free PMC article.
19 results